Navigation Links
FDA Approves New Treatment for Advanced Form of Kidney Cancer
Date:10/19/2009

SILVER SPRING, Md., Oct. 19 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

Votrient is an oral medication that interferes with angiogenesis, the growth of new blood vessels needed for solid tumors to grow and survive.

Votrient is intended for people with advanced renal cell carcinoma, a type of kidney cancer in which the cancerous cells are found in the lining of very small tubes (tubules) in the kidney. In 2009, approximately 49,000 people were diagnosed with renal cell carcinoma and 11,000 people died from the disease.

"The last five years have seen dramatic improvements in treatment options for patients with kidney cancer. Before 2005, the options available offered only limited effectiveness," said Richard Pazdur, M.D., director, Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research.

The five other drugs approved for kidney cancer and their approval dates are: Sorafenib (December 2005), Sunitinib (January 2006), Temsirolimus (May 2007), Everolimus (March 2009), and Bevacizumab (July 2009).

The safety and effectiveness of Votrient was evaluated in a 435-patient study that examined a patient's progression-free survival - the length of time, following enrollment in the study, before the tumor began growing again or before the patient died. Progression-free survival averaged 9.2 months for patients receiving Votrient compared to 4.2 months for patients who did not receive the drug.

Adverse reactions included diarrhea, high blood pressure, hair color changes, nausea, loss of appetite, vomiting, fatigue, weakness, abdominal pain and headache. Votrient can also cause severe and fatal liver toxicity. Hea
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy
2. FDA Approves Cervarix, GlaxoSmithKlines Cervical Cancer Vaccine
3. U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
4. Chinese Food and Drug Administration Approves Gabexate Mesylate as Pharmaceutical Raw Material
5. FDA Approves New Indication For Mirena(R) to Treat Heavy Menstrual Bleeding in IUD Users
6. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
7. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
8. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
9. FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
10. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
11. FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- Market Research ... Industry, 2009-2019 is a professional and in-depth market ... Scanner industry . The report firstly reviews the ... classification, application and manufacturing technology. The report then ... Crystallography Scanner listing their product specification, capacity, Production ...
(Date:8/29/2014)... 2014 The clinical and medical insights provided ... between a product,s success or failure. Despite this, many ... targets – and then to coordinate activities and outreach ... upon which successful KOL engagement rests. ... internal inconsistencies in their KOL management systems and are ...
(Date:8/29/2014)... /PRNewswire-iReach/ -- SAM Medical Products Implements Voluntary Recall ... Junctional Tourniquet.  Photo - ... announced today that it has begun notifying customers ... issue with a clip used to secure the ... the SAM Junctional Tourniquet (SJT).  The company discovered ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5Implementing a Strategic Thought Leader Management & Engagement System 2SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2
... to Phase 3; Eligible for Accelerated Approval; ... Global Regulatory Plan Expected by Year End, CRANBURY, ... a biopharmaceutical company developing small molecule,orally-administered pharmacological chaperones for ... has successfully completed an End,of Phase 2 meeting for ...
... Rare Genetic Disorder in,Children--, PHILADELPHIA, July 31 ... levels of blood sugar in animals genetically,engineered to ... in humans, it could become an innovative medicine ... devastating genetic,disease in which insulin levels become dangerously ...
Cached Medicine Technology:Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease 2Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease 3Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease 4Treatment Corrects Severe Insulin Imbalance in Animal Studies 2Treatment Corrects Severe Insulin Imbalance in Animal Studies 3
(Date:9/2/2014)... 02, 2014 The Quantum Group, ... Quantum Innovations, Inc . (QI), it has submitted ... MU2 Certification with a private IT security laboratory approved ... The platform has Meaningful Use 1 certification status (see ... approved and 15 pending patents. The accrediting organization has ...
(Date:9/2/2014)... public support for marijuana legalization in the U.S. has ... than other substances, such as alcohol. In January, President ... marijuana is more dangerous than alcohol. Despite the recent ... as compared to alcohol use are not well understood. ... Outcomes Associated with Drug Use among US High School ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 At the ... Prosupps will be an exhibitor at the Las ... Rd, Las Vegas, NV 89109 Booth #374 Sept 19th ... to encourage healthy living through exercise, diet and supplementation. ... vision, and provide the tools for all Prosupps customers ...
(Date:9/2/2014)... Smile Squared, a well-known Buy One, Give ... a US-made toothbrush. For every toothbrush purchased, Smile Squared ... Squared was created by my wife and me after ... Cope, President of Smile Squared. “There, we saw children ... many of the same children didn't own a toothbrush. ...
(Date:9/2/2014)... Tuesday 2 September 2014: Digoxin may increase the ... by approximately 20%, according to results from the ROCKET ... Manesh Patel, director of interventional cardiology and catheterisation labs ... US. The findings suggest that caution may be needed ... studies are needed to confirm the observations. , Dr ...
Breaking Medicine News(10 mins):Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 2Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 3Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 4Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 5Health News:NYU study compares consequences of teen alcohol and marijuana use 2Health News:NYU study compares consequences of teen alcohol and marijuana use 3Health News:Prosupps, One of the Fastest Growing Supplement Companies, Celebrates a Success Milestone with Exhibiting at the 50th Annual 2014 Mr. Olympia’s Fitness & Performance Expo 2Health News:Smile Squared's Colorful Buy One, Give One Toothbrush Now Available in Schnucks Stores 2Health News:ROCKET AF trial suggests that digoxin increases risk of death in AF patients 2
... MISSISSAUGA, ON, May 13 /PRNewswire-FirstCall/ - Cipher Pharmaceuticals,Inc. ... Drug Application (NDA),has been submitted to the U.S. ... extended-release formulation of tramadol. In May 2007,the Company ... to its,NDA for CIP-TRAMADOL ER., Cipher,s revised ...
... May 13 Lumenis Inc., a global,developer, ... radiofrequency,devices for surgical, aesthetic, and ophthalmic applications, ... Enucleation of the Prostate (HoLEP),preceptor program that ... interested in learning and performing HoLEP. The ...
... Project proceeds despite non-compliance with California Environmental ... Quality ... Center (PHCMC) today went ahead with the planned expansion of its,Holy ... has upheld charges that the approval process was significantly flawed.,The groundbreaking ...
... 12 /PRNewswire-FirstCall/ - Med-Emerg International Inc.,(OTCBB - MDER), ... three months ended March 31, 2008 were $5.5 ... in 2007 (all amounts are $US unless,otherwise stated). ... interest and taxes (EBITDA) improved to $179K,from a ...
... TSX:,WHT) World Heart Corporation ("WorldHeart" or the "Corporation") ... Bulletin today advising it,is reviewing the eligibility for ... of WorldHeart under sections 709 and 710(a) of ... Company,s financial condition and,operating results, more specifically whether ...
... Institute (KGI),today announced that the May 17, 2008, commencement ... Applied Life Sciences student, Eric,Tan, and the unveiling of ... and proud of Eric,s achievement in becoming the,first graduate ... KGI,s senior,vice president for academic affairs, dean of faculty ...
Cached Medicine News:Health News:Cipher provides regulatory update for CIP-TRAMADOL ER 2Health News:Cipher provides regulatory update for CIP-TRAMADOL ER 3Health News:Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting 2Health News:Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting 3Health News:Providence Holy Cross Medical Center Ignores Community, Environmental Concerns With Planned Expansion of Mission Hills Facility 2Health News:Med-Emerg International Inc. reports improved income from continuing operations 2Health News:Med-Emerg International Inc. reports improved income from continuing operations 3Health News:WorldHeart Notified of TSX Delisting Review 2Health News:KGI 2008 Commencement Features First PhD Graduate, Biotech Painting 2
... The ImmunoWELL VZV IgG ... for the qualitative detection of ... (VZV). Test results are used ... status or infection. Immune status ...
... Test is an enzyme immunoassay (EIA) test ... human thyroglobulin and human thyroid peroxidase (microsome) ... is used as an aid in the ... disorders are characterized by detection of anti-thyroid ...
... ImmunoDOT Autoimmunity Screening Panel 1 is ... screening and detection of autoantibodies against ... SS-A/SS-B, RNP/Sm) in serum, and is ... diagnosis of systemic lupus erythematosus (SLE), ...
... Antibody (IgG) Test is an ... quantitative detection of antibodies to ... is used as an aid ... thrombosis in individuals with systemic ...
Medicine Products: